Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) is expected to post its Q1 2025 quarterly earnings results after the market closes on Monday, May 12th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.
Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). On average, analysts expect Atea Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Atea Pharmaceuticals Price Performance
Shares of AVIR stock traded down $0.04 during trading hours on Friday, reaching $2.72. The company had a trading volume of 372,498 shares, compared to its average volume of 303,478. Atea Pharmaceuticals has a 1-year low of $2.60 and a 1-year high of $4.15. The firm has a market cap of $232.77 million, a price-to-earnings ratio of -1.31 and a beta of 0.17. The company has a 50 day moving average of $2.93 and a 200 day moving average of $3.12.
Analyst Upgrades and Downgrades
Several brokerages have commented on AVIR. Morgan Stanley lowered their target price on shares of Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating for the company in a research note on Friday, April 11th. William Blair reaffirmed an "outperform" rating on shares of Atea Pharmaceuticals in a research note on Friday, March 7th.
Read Our Latest Analysis on Atea Pharmaceuticals
Atea Pharmaceuticals Company Profile
(
Get Free Report)
Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.
Read More

Before you consider Atea Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atea Pharmaceuticals wasn't on the list.
While Atea Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.